Comparative Analysis of efficay and safety in eradication therapy as 3rd line, PPI+AMPC+LVFX versus high dose PPI+AMPC

Comparative Analysis of efficay and safety in eradication therapy as 3rd line, PPI+AMPC+LVFX versus high dose PPI+AMPC - Eradication therapy as 3rd line, versus high dose PPI+AMPC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005373

Enrollment

Registered

2011-04-14

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with H. pylori infection who failed 2nd line of eradication therapy

Interventions

PPI AMPC LVFX HIgh dose of PPI AMPC

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patinets who failed 2nd line of Hp eradication therapy

Exclusion criteria

Exclusion criteria: Allergy for PPI AMPC LVFX pregnancy nursing a baby

Design outcomes

Primary

Measure	Time frame
The efficacy and safety in 3rd line of Hp eradication therapy	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026